Health Canada to start real-time review of Pfizer-BioNTech COVID-19 vaccine
(Reuters) – Health Canada will start a real-time review of Germany’s BioNTech SE and Pfizer Inc’s experimental COVID-19 vaccine, the companies said on Friday.
The companies said they would submit safety and efficacy data from the trial of their COVID-19 vaccine to Canada’s health ministry under a rolling submission as and when it becomes available.
A rolling review allows researchers to submit findings in real time, without waiting for studies to conclude. Canadian health minister Patty Hajdu last month signed an order allowing companies developing COVID-19 vaccines to submit information as it becomes available.
Health Canada said it will not make a decision on whether to authorize any vaccine under rolling review until it has received the necessary evidence to support the candidate’s safety, efficacy
